FDA approves tesamorelin for HIV patients with lipodystrophy
Canada-based Theratechnologies announced that FDA has approved tesamorelin (Egrifta) to treat HIV patients with lipodystrophy. The condition is associated with many antiretroviral drugs used to treat HIV.
Canada-based Theratechnologies announced that FDA has approved tesamorelin (Egrifta) to treat HIV patients with lipodystrophy. The condition is associated with many antiretroviral drugs used to treat HIV.
Tesamorelin is the first FDA-approved treatment for lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs. It is a growth hormone releasing factor drug that is administered in a once-daily injection.
FDA’s approval of tesamorelin was based on 2 clinical trials involving 816 HIV-infected adults with lipodystrophy and excess abdominal fat. In both studies, patients treated with tesamorelin experienced greater reductions in abdominal fat as measured by CT scan, compared with patients receiving a placebo. Some patients using tesamorelin reported improvements in their self-image.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More
